Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02480816
Other study ID # BW-13
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2015
Est. completion date February 1, 2016

Study information

Verified date September 2018
Source National Research Council, Spain
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effects of consuming a sodium-bicarbonated mineral water rich in bicarbonate, sodium, chloride, lithium and silicon are studied in humans. The aim of this assay was to determine whether the consumption of this water as part of the usual diet, reduces cardiometabolic risk factors in adult men and women.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date February 1, 2016
Est. primary completion date November 1, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy adults, men and women >18 and = 45 years

- Total-cholesterol > 200 mg/dL and < 300 mg/dL

Exclusion Criteria:

- Age <18 and > 45 years

- Total-cholesterol =300 mg/dL

- Triglycerides > 250 mg/dL

- Total-cholesterol / HDL-cholesterol > 6

- Being a usual consumer of carbonic mineral water

- BMI < 20 and >30 kg/m2

- Diabetes

- Hypertension or digestive, liver or renal disease

- Eating disorders

- Being under medication that could affect lipid metabolism

- Consumption of functional foods that could affect lipid metabolism (food containing n-3 fatty acids or phytosterols)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Mineral water
Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Research Council, Spain

References & Publications (1)

Toxqui L, Vaquero MP. An Intervention with Mineral Water Decreases Cardiometabolic Risk Biomarkers. A Crossover, Randomised, Controlled Trial with Two Mineral Waters in Moderately Hypercholesterolaemic Adults. Nutrients. 2016 Jun 28;8(7). pii: E400. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary LDL-cholesterol Baseline
Primary LDL-cholesterol 4 weeks
Primary LDL-cholesterol 8 weeks
Secondary Total-cholesterol Baseline
Secondary Total-cholesterol 4 weeks
Secondary Total-cholesterol 8 weeks
Secondary Triglycerides Baseline
Secondary Triglycerides 4 weeks
Secondary Triglycerides 8 weeks
Secondary HDL-cholesterol Baseline
Secondary HDL-cholesterol 4 weeks
Secondary HDL-cholesterol 8 weeks
Secondary Apolipoprotein A Baseline
Secondary Apolipoprotein A 4 weeks
Secondary Apolipoprotein A 8 weeks
Secondary Apolipoprotein B Baseline
Secondary Apolipoprotein B 4 weeks
Secondary Apolipoprotein B 8 weeks
Secondary Glucose Baseline
Secondary Glucose 4 weeks
Secondary Glucose 8 weeks
Secondary Insulin Baseline
Secondary Insulin 4 weeks
Secondary Insulin 8 weeks
Secondary Urine creatinin Baseline
Secondary Urine creatinin 8 weeks
Secondary Urine calcium Baseline
Secondary Urine calcium 8 weeks
Secondary Urine potassium Baseline
Secondary Urine potassium 8 weeks
Secondary Urine sodium Baseline
Secondary Urine sodium 8 weeks
Secondary Urine pH Baseline
Secondary Urine pH 8 weeks
Secondary Systolic Blood Pressure Baseline
Secondary Systolic Blood Pressure 4 weeks
Secondary Systolic Blood Pressure 8 weeks
Secondary Diastolic Blood Pressure Baseline
Secondary Diastolic Blood Pressure 4 weeks
Secondary Diastolic Blood Pressure 8 weeks
Secondary Oxidized LDL Baseline
Secondary Oxidized LDL 4 weeks
Secondary Oxidized LDL 8 weeks
Secondary Serum aldosterone Baseline
Secondary Serum aldosterone 8 weeks
Secondary BMI Baseline
Secondary BMI 4 weeks
Secondary BMI 8 weeks
Secondary Dietary energy intake Baseline
Secondary Dietary energy intake 8 weeks
Secondary Dietary protein intake Baseline
Secondary Dietary protein intake 8 weeks
Secondary Dietary fat intake Baseline
Secondary Dietary fat intake 8 weeks
Secondary Dietary cholesterol intake Baseline
Secondary Dietary cholesterol intake 8 weeks
Secondary Dietary carbohydrate intake Baseline
Secondary Dietary carbohydrate intake 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT02837367 - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People N/A
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01764295 - Clinical Study for Patients With Hypertension Associated With Dyslipidemia Phase 3
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Completed NCT01531062 - Effect of Nigella Sativa on Lipid Profiles in Elderly Phase 2
Terminated NCT01414166 - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) Phase 3
Recruiting NCT01670968 - HIV Reverse Cholesterol Transport Study
Completed NCT00977288 - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) Phase 2
Withdrawn NCT00664287 - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) Phase 3
Completed NCT00768274 - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol Phase 1/Phase 2
Completed NCT01285544 - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia Phase 4
Completed NCT01483235 - Reduced Cardiac Rehabilitation Program N/A
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Terminated NCT00816829 - Effect of Fenofibrate on Sleep Apnea Syndrome Phase 2